med fusion Launches HemeSEQ, Hematologic Neoplasm Profiles In Collaboration With The US Oncology Network

LEWISVILLE, Texas--(BUSINESS WIRE)--med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, announced the expansion of its oncology testing services to include the new HemeSEQ portfolio of next generation sequencing (NGS) profiles. The HemeSEQ profiles cover four hematologic neoplasms: Acute Myeloid Leukemia (AML Profile), Chronic Lymphocytic Leukemia (CLL Profile), Diffuse Large B-Cell Lymphoma (DLBCL Profile) and Myeloproliferative Neoplasms (MPN Profile). These disease-specific profiles embody med fusion’s commitment to creating responsible precision medicine solutions through cost effective analysis of clinically actionable alterations.

“Detection of genetic alterations in hematological malignancies enables the clinician to broadly understand the genetic blueprint of the disease in order to quickly and accurately make a diagnosis as well as identify possible targets for treatment”

Understanding the pathobiology of hematologic diseases and the effective management of patients with these diseases depend on data from accurate molecular diagnostic tests. To help meet this need, med fusion developed the HemeSEQ profiles which expand its hematologic menu to nearly 100 tests and incorporate NGS technology to more thoroughly interrogate the genetic basis of a patient’s disease.

Results from med fusion’s comprehensive analysis are matched with relevant clinical trials and therapy options based on the specific genomic signature of the patient’s disease. The cumulative findings are delivered via an integrated report that includes cytogenetic abnormalities and molecular mutations identified for each patient, as recommended by The World Health Organization’s 2016 classification of tumors of the hematopoietic and lymphoid tissues. The final report is easy to read and delivers oncologists a powerful tool to efficiently complete evidence-based diagnostic and prognostic assessments of patients living with hematologic disease.

“Detection of genetic alterations in hematological malignancies enables the clinician to broadly understand the genetic blueprint of the disease in order to quickly and accurately make a diagnosis as well as identify possible targets for treatment,” said Roger Lyons, MD, FACP, hematologist with Texas Oncology-San Antonio Medical Center and chairman of the Hematology Committee for The US Oncology Network.

“Our ultimate goal at med fusion is to help improve patient care,” said Jon Hart, CEO of med fusion. “We believe the best way to accomplish this is by providing physicians with responsible precision medicine tools that deliver actionable results quickly. Our new hematologic neoplasm profiles exemplify our approach, and we look forward to their contribution to patient care for patients with AML, CLL, DLBCL and MPN.”

About med fusion

med fusion, an integrated Roche Molecular Center for Excellence and clinical trials service organization, delivers support to healthcare providers and biotech/pharmaceutical companies to consistently meet the needs of patients. An industry leader in advanced laboratory diagnostics and support, our full service clinical laboratory includes a dedicated test development and validation team to meet the needs of clients and reference lab services such as pathology and molecular diagnostics. med fusion is committed to facilitate the realization of responsible precision medicine by specializing in: Oncology, Women’s Health, Urology, and Infectious Disease. Headquartered in Lewisville, Texas, med fusion offers its specialized services throughout the U.S. To learn more, please visit www.medfusionservices.com.